ZA201400236B - Combination als therapy - Google Patents
Combination als therapyInfo
- Publication number
- ZA201400236B ZA201400236B ZA2014/00236A ZA201400236A ZA201400236B ZA 201400236 B ZA201400236 B ZA 201400236B ZA 2014/00236 A ZA2014/00236 A ZA 2014/00236A ZA 201400236 A ZA201400236 A ZA 201400236A ZA 201400236 B ZA201400236 B ZA 201400236B
- Authority
- ZA
- South Africa
- Prior art keywords
- combination
- als therapy
- als
- therapy
- combination als
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507381P | 2011-07-13 | 2011-07-13 | |
| US201161544533P | 2011-10-07 | 2011-10-07 | |
| US201261637759P | 2012-04-24 | 2012-04-24 | |
| US201261637770P | 2012-04-24 | 2012-04-24 | |
| US201261646699P | 2012-05-14 | 2012-05-14 | |
| PCT/US2012/046523 WO2013010015A2 (en) | 2011-07-13 | 2012-07-12 | Combination als therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201400236B true ZA201400236B (en) | 2014-10-29 |
Family
ID=47506929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/00236A ZA201400236B (en) | 2011-07-13 | 2014-01-10 | Combination als therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10272082B2 (enExample) |
| EP (1) | EP2731611B1 (enExample) |
| JP (2) | JP6145946B2 (enExample) |
| KR (1) | KR101951220B1 (enExample) |
| CN (2) | CN104039148A (enExample) |
| AU (2) | AU2012281042B2 (enExample) |
| BR (1) | BR112014000742A2 (enExample) |
| CA (1) | CA2849213A1 (enExample) |
| EA (2) | EA028060B1 (enExample) |
| HK (1) | HK1197178A1 (enExample) |
| IL (1) | IL230391B (enExample) |
| IN (1) | IN2014DN00200A (enExample) |
| PH (1) | PH12014500094A1 (enExample) |
| SG (1) | SG10201605707UA (enExample) |
| WO (1) | WO2013010015A2 (enExample) |
| ZA (1) | ZA201400236B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| WO2015063318A1 (en) * | 2013-11-04 | 2015-05-07 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
| PL3137622T3 (pl) * | 2014-04-29 | 2022-05-09 | Cytokinetics, Inc. | Sposoby redukowania spadku pojemności życiowej |
| BR112017010440A2 (pt) * | 2014-11-21 | 2017-12-26 | Biohaven Pharm Holding Co Ltd | administração sublingual de riluzol |
| HUE046869T2 (hu) * | 2014-11-21 | 2020-04-28 | Biohaven Therapeutics Ltd | Riluzol szublingvális formulációja |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| BR112018069515A2 (pt) | 2016-03-25 | 2019-04-16 | Ab Science | uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica |
| WO2021055890A1 (en) | 2019-09-20 | 2021-03-25 | Icahn School Of Medicine At Mount Sinai | Controlled release formulations of riluzole and their uses |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| IT1156732B (it) | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
| US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
| US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
| US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
| JPH0641135A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| KR20010052570A (ko) | 1998-06-04 | 2001-06-25 | 스티븐 에프. 웨인스톡 | 세포 유착을 억제하는 소염성 화합물 |
| PT1218382E (pt) | 1999-10-08 | 2004-06-30 | Gruenenthal Gmbh | Derivados de imidazo-3-il-amina biciclica |
| PT1218383E (pt) | 1999-10-08 | 2009-01-29 | Gruenenthal Gmbh | Derivados bicíclicos de imidazo-5-il-amina |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
| US20040235801A1 (en) | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| WO2005013894A2 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| CN1816530A (zh) | 2003-07-01 | 2006-08-09 | 麦克公司 | 用于治疗高眼压症的眼用组合物 |
| US20050250794A1 (en) | 2003-12-19 | 2005-11-10 | Andrew Napper | Methods of treating a disorder |
| AU2005208938A1 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Anti-viral therapeutics |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006036883A2 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| MX2007010068A (es) | 2005-02-16 | 2007-10-10 | Schering Corp | Piperazino-piperidinas con actividad antagonista de cxcr3. |
| US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
| JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US20090082370A1 (en) | 2006-04-25 | 2009-03-26 | Neil Thomas Thompson | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US20100173930A1 (en) | 2006-08-01 | 2010-07-08 | Alex Muci | Certain Chemical Entities, Compositions and Methods |
| SI2069352T1 (sl) * | 2006-08-02 | 2013-12-31 | Cytokinetics, Inc. | Določene kemijske entitete, sestavki in postopki |
| DK2069352T5 (en) * | 2006-08-02 | 2017-04-03 | Cytokinetics Inc | SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| US7981893B2 (en) | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| BRPI0806898A2 (pt) | 2007-01-19 | 2015-07-14 | Ardea Biosciences Inc | Inibidores de mek |
| EP2139478A4 (en) | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| EP2018854A1 (en) * | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| CN101983061A (zh) | 2008-02-04 | 2011-03-02 | 赛特凯恩蒂克公司 | 某种化学物质、组合物和方法 |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| WO2010004031A2 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
| AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| CN102802418A (zh) * | 2009-06-19 | 2012-11-28 | 诺普神经科学股份有限公司 | 用于治疗肌萎缩性侧索硬化的组合物和方法 |
| BR112014024552A2 (pt) | 2012-04-02 | 2017-09-19 | Cytokinetics Inc | método para aprimorar a função do diafragma em um paciente que necessite do mesmo; método para aumentar a função, atividade, eficiência, sensibilidade ao cálcio ou tempo de fadiga do músculo esquelético no diafragma de um paciente que necessite do mesmo e método para aumentar a função, atividade, eficiência, força, sensibilidade ao cálcio ou tempo de fadiga de uma fibra muscular esquelética do diafragma. |
| EA032480B1 (ru) | 2012-04-11 | 2019-06-28 | Сайтокинетикс, Инк. | Способы повышения устойчивости скелетных мышц к утомлению |
| PL3137622T3 (pl) | 2014-04-29 | 2022-05-09 | Cytokinetics, Inc. | Sposoby redukowania spadku pojemności życiowej |
-
2012
- 2012-07-12 US US14/131,649 patent/US10272082B2/en not_active Expired - Fee Related
- 2012-07-12 HK HK14110537.3A patent/HK1197178A1/xx unknown
- 2012-07-12 KR KR1020147000783A patent/KR101951220B1/ko not_active Expired - Fee Related
- 2012-07-12 CA CA2849213A patent/CA2849213A1/en not_active Abandoned
- 2012-07-12 AU AU2012281042A patent/AU2012281042B2/en not_active Ceased
- 2012-07-12 EA EA201490011A patent/EA028060B1/ru not_active IP Right Cessation
- 2012-07-12 PH PH1/2014/500094A patent/PH12014500094A1/en unknown
- 2012-07-12 CN CN201280034661.5A patent/CN104039148A/zh active Pending
- 2012-07-12 CN CN201811116043.0A patent/CN109316480A/zh active Pending
- 2012-07-12 BR BR112014000742A patent/BR112014000742A2/pt not_active Application Discontinuation
- 2012-07-12 SG SG10201605707UA patent/SG10201605707UA/en unknown
- 2012-07-12 JP JP2014520335A patent/JP6145946B2/ja not_active Expired - Fee Related
- 2012-07-12 WO PCT/US2012/046523 patent/WO2013010015A2/en not_active Ceased
- 2012-07-12 EP EP12811325.5A patent/EP2731611B1/en active Active
- 2012-07-12 IN IN200DEN2014 patent/IN2014DN00200A/en unknown
- 2012-07-12 EA EA201791043A patent/EA201791043A1/ru unknown
-
2014
- 2014-01-09 IL IL230391A patent/IL230391B/en active IP Right Grant
- 2014-01-10 ZA ZA2014/00236A patent/ZA201400236B/en unknown
-
2016
- 2016-10-13 AU AU2016244263A patent/AU2016244263A1/en not_active Abandoned
-
2017
- 2017-04-28 JP JP2017090313A patent/JP2017128610A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109316480A (zh) | 2019-02-12 |
| JP2014520856A (ja) | 2014-08-25 |
| PH12014500094A1 (en) | 2014-03-17 |
| BR112014000742A2 (pt) | 2016-08-23 |
| AU2016244263A1 (en) | 2016-11-03 |
| EA201791043A1 (ru) | 2017-09-29 |
| EA028060B1 (ru) | 2017-10-31 |
| CN104039148A (zh) | 2014-09-10 |
| US20140243344A1 (en) | 2014-08-28 |
| JP6145946B2 (ja) | 2017-06-14 |
| JP2017128610A (ja) | 2017-07-27 |
| IN2014DN00200A (enExample) | 2015-06-05 |
| IL230391B (en) | 2019-03-31 |
| HK1197178A1 (en) | 2015-01-09 |
| US10272082B2 (en) | 2019-04-30 |
| NZ619924A (en) | 2016-02-26 |
| KR101951220B1 (ko) | 2019-02-22 |
| AU2012281042A1 (en) | 2014-01-30 |
| EP2731611A4 (en) | 2015-02-18 |
| EP2731611A2 (en) | 2014-05-21 |
| CA2849213A1 (en) | 2013-01-17 |
| SG10201605707UA (en) | 2016-09-29 |
| AU2012281042B2 (en) | 2016-07-14 |
| WO2013010015A2 (en) | 2013-01-17 |
| WO2013010015A3 (en) | 2014-05-15 |
| EP2731611B1 (en) | 2019-09-18 |
| KR20140074270A (ko) | 2014-06-17 |
| EA201490011A1 (ru) | 2014-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201305897B (en) | Combination therapy | |
| GB201212513D0 (en) | Therapeutic agents | |
| IL222481A0 (en) | Combination therapy | |
| EP2552323A4 (en) | COMBINATION THERAPY | |
| ZA201400120B (en) | Combination therapy | |
| GB201106803D0 (en) | Sonodynamic therapy | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| PL2489413T3 (pl) | Przyrząd terapeutyczny | |
| GB201217439D0 (en) | Combination therapy | |
| SG10201605707UA (en) | Combination als therapy | |
| GB201217704D0 (en) | Therapeutic agents | |
| PL2723330T3 (pl) | Lek kombinowany zawierający środek naczynioskurczowy | |
| ZA201502595B (en) | Therapeutic methods | |
| EP2701744A4 (en) | COMBINATION THERAPY | |
| GB201207305D0 (en) | Therapy | |
| GB201005394D0 (en) | Therapy | |
| EP2704731A4 (en) | TREATMENT OF AVIAN ORIGIN | |
| GB201106630D0 (en) | Cancer therapy | |
| EP2629766A4 (en) | COMBINATION THERAPY | |
| GB201102913D0 (en) | Novel therapeutic | |
| GB201114226D0 (en) | Combination therapy | |
| GB201120096D0 (en) | Novel therapy | |
| GB201110614D0 (en) | Therapeutic agents | |
| GB201101128D0 (en) | Therapeutic agents |